Velcera Appoints Sal Uglietta to Board of Directors

YARDLEY, PA, Jun 19 (MARKET WIRE) --
Velcera, Inc. (OTCBB: VLCR), a specialty pharmaceutical company focused
on pet health, announced today the appointment of Sal J. Uglietta to the
Company's board of directors.

"We are delighted to welcome Mr. Uglietta to our board. His demonstrated
strategic marketing and executive skills will contribute to our business
growth. I look forward to working closely with Sal as we build new value
for Velcera investors," said Dennis Steadman, Velcera's President and
Chief Executive Officer.

Mr. Uglietta is Executive Vice President, Healthcare Practice Leader with
SWAT Team Partners LLC, a leading national organization specializing in
strategic business and marketing consulting. Sal is a highly regarded
healthcare executive whose 30-year career encompasses successful domestic
and international growth experiences in consumer healthcare,
pharmaceuticals, national health plans and provider organizations.
Previously Mr. Uglietta has held numerous positions in the healthcare
field, including Head of Marketing and President to InteliHealth, Inc., a
division of Aetna partnered with the Harvard Medical School; the Vice
President of Marketing and Sales of Johnson & Johnson-Merck Joint Venture
and European OTC Business Head of Johnson & Johnson. Mr. Uglietta holds a
BS degree from Brandeis University and an MBA in Marketing and
International Business from Columbia University.

About Velcera, Inc.

Velcera is a specialty pharmaceutical company focused on innovation in the
expanding pet health market. Velcera's product development targets new pet
medicines in pain management, anti-allergy and parasiticides that can
provide superior convenience and greater compliance than traditional
products. Certain product candidates are based upon the patented Promist
delivery technology, which has the potential to increase compliance and
improve pet health as owners avoid the challenges of getting pets to
swallow pills.

This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such statements
involve risks and uncertainties that could cause our actual results to
differ materially from the anticipated results and expectations expressed
in these forward-looking statements. These statements are often, but not
always, made through the use of words or phrases such as "anticipates,"
"expects," "plans," "believes," "intends," and similar words or phrases.
These statements are based on current expectations, forecasts and
assumptions that are subject to risks and uncertainties, which could cause
actual outcomes and results to differ materially from these statements.
Risks that may affect forward-looking information contained in this press
release include, without limitation, the risk that the results of clinical
trials may not support our claims and our lack of experience in developing
and commercializing pet pharmaceutical products. Additional risks are
described in our post effective-amendment No. 1 on Form S-1 to our SB-2/A
Registration Statement filed on April 28, 2008.We assume no obligation to
update these statements, except as required by law.

Contact:
Dennis Streadman
CEO
267 757 3600

Copyright 2008, Market Wire, All rights reserved.

-0-